Jump to content

Eisai (company)

From Wikipedia, the free encyclopedia

Eisai Co., Ltd.
Native name
Ēzai kabushiki gaisha
Company typePublic KK
TYO: 4523
TOPIX Large 70 Component
TOPIX 100 Component
Nikkei 225 Component
FoundedDecember 6, 1941; 82 years ago (1941-12-06)
FounderToyoji Naito
Headquarters4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan
Key people
Haruo Naito
(President and CEO)
RevenueIncrease ¥ 680 billion (2019)[1]
Increase ¥ 103 billion (2019)[1]
Increase ¥ 72.5 billion (2019)[1]
Total assetsIncrease ¥ 1,071 billion (2019)[1]
Total equityIncrease ¥ 652 billion (2019)[1]
OwnerThe Master Trust Bank of Japan (11.78%)
Japan Trustee Services Bank (10.99%)
Nippon Life (4.29%)[1]
Number of employees
Increase 1,864 (2019)[1]
WebsiteOfficial website
Footnotes / references
[citation needed]

Eisai Co., Ltd. (Japanese: エーザイ株式会社, Hepburn: Ēzai Kabushiki-gaisha) is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.[2]


Nihon Eisai Co. Ltd. was established in 1941.[3] In 1944, merger with Sakuragaoka Research Laboratory resulted in creation of Eisai Co. Ltd.[4] The American subsidiary of the company, Eisai Inc., was established in 1995.[5]

On November 25, 1996, Eisai received approval from the United States Food and Drug Administration (USFDA) for Aricept (donepezil), a drug discovered in the company's labs and co-marketed with Pfizer.[6]

Three years later in 1999, the company received USFDA approval for Aciphex (rabeprazole), a drug co-marketed with Johnson & Johnson.

In September 2006, the company acquired four oncology products from Ligand Pharmaceuticals.[7]

In April 2007, Eisai acquired Exton, Pennsylvania-based Morphotek, a company developing therapeutic monoclonal antibodies for the treatment of cancer, rheumatoid arthritis, and infectious diseases.

In December 2007, Eisai acquired MGI Pharma, a company specializing in oncology, for US$3.9 billion.[8] This event brought Dacogen (decitabine), Aloxi (palonosetron), Hexalen (altretamine) for ovarian cancer, and the Gliadel Wafer (carmustine) for brain tumors into the Eisai product portfolio.

In 2009, Eisai received the Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Banzel (rufinamide).[9]

In June 2023, the company suffered from a ransomware attack, causing a shutdown of some of its logistical systems.[10]


Eisai Co., Ltd. is based in Tokyo, Japan, while its American subsidiary, Eisai Inc., is headquartered in Nutley, New Jersey. Eisai Inc. is led by Ivan Cheung as CEO.[11] Eisai maintains medical research headquarters in Nutley as well as at locations in Japan, the United Kingdom, the Research Triangle in North Carolina, and Massachusetts where the Eisai Research Institute and the Genetics Guided Dementia Discovery (G2D2) institute are based.[12][13]

The company has manufacturing sites in Japan, North Carolina (USA), Maryland (USA), Bogor (Indonesia), Suzhou (China), Tainan (Taiwan), Visakhapatnam (India) and Hatfield, Hertfordshire (UK). Eisai has marketing operations in 19 European countries as well as the Asia-Pacific region.


Some of the key products that Eisai produces or markets with partners include:


Aricept accounted for 40% of Eisai's revenue as of March 2010.[14] The main competitor to Aricept is a generic formulation from Ranbaxy Labs.[14] Eisai has pursued development of alternative formulations in order to extend the marketable lifetime of the product.[14]

See also[edit]


  1. ^ a b c d e f g "Eisai Financial Summary 2019" (PDF). Retrieved December 21, 2020.
  2. ^ "Components:Nikkei Stock Average". Nihon Keizai Shimbun. Retrieved February 9, 2015.
  3. ^ "Eisai: The First 80 Years | Eisai Co., Ltd".
  4. ^ Winograd, Claudia (October 16, 2007). "Eisai (Japan)". In Colditz, Graham A. (ed.). Encyclopedia of Cancer and Society. SAGE Publications. doi:10.4135/9781412953979. ISBN 9781412949897. Archived from the original on February 9, 2015. Retrieved February 9, 2015.
  5. ^ "Lonnel Coats Appointed President & Chief Executive Officer of Eisai Inc" (Press release). Businesswire. Retrieved February 9, 2015.
  6. ^ "27 Nov 1996, Page 11 - The Cincinnati Enquirer at". Newspapers.com. November 27, 1996. Retrieved June 5, 2022.
  7. ^ "Eisai Inc. Buys 4 Cancer Drugs From Ligand Pharmaceuticals Inc. For $205 Million". BioSpace. Retrieved February 21, 2020.
  8. ^ "Japan's Eisai to buy MGI Pharma for $3.9 bln". Reuters. December 10, 2007. Retrieved November 20, 2019.
  9. ^ "NORD to Honor Rare Disease Pioneers". PR Newswire. May 11, 2009. Archived from the original on February 9, 2015. Retrieved February 9, 2015.
  10. ^ "Pharmaceutical Giant Eisai Takes Systems Offline Following Ransomware Attack". June 8, 2023.
  11. ^ Bell, Jacob (February 6, 2023). "Eisai gives first glimpse into Alzheimer's drug launch". BiopharmaDive. Washington, D.C.: Informa. Archived from the original on February 6, 2023. Retrieved February 11, 2023.
  12. ^ Carroll, John (September 15, 2016). "Eisai launches biotech division in Massachusetts aimed at Alzheimer's, I/O and autoimmune diseases". Endpoint News. Retrieved November 4, 2016.
  13. ^ "Eisai Launches Facility to Advance Precision Medicine". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). October 15, 2016. p. 8.
  14. ^ a b c Kanoko Matsuyama (April 25, 2011). "Eisai Aricept Patch for Alzheimer's Isn't Ready for Approval". Bloomberg L.P. Retrieved April 25, 2011.

External links[edit]